Robert Hilbrands

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Journal: Lancet (London, England)

Published: July 07, 2025

Identity and bodily experiences in emerging adults with type 1 diabetes (T1D): a qualitative exploration.

Identity and bodily experiences in emerging adults with type 1 diabetes (T1D): a qualitative exploration.

Journal: Psychology & health

Published: May 09, 2025

Finding Stability for Unstable Glucose.

Finding Stability for Unstable Glucose.

Journal: Diabetes care

Published: February 26, 2025

Stability and change of illness identity in Belgian youth with type 1 diabetes: a latent transition analysis.

Stability and change of illness identity in Belgian youth with type 1 diabetes: a latent transition analysis.

Journal: Annals of behavioral medicine : a publication of the Society of Behavioral Medicine

Published: December 11, 2024

Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.

Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.

Journal: Frontiers in endocrinology

Published: July 05, 2024

Comparing youth with and without type 1 diabetes on perceived parenting and peer functioning: a propensity weighting approach.

Comparing youth with and without type 1 diabetes on perceived parenting and peer functioning: a propensity weighting approach.

Journal: Journal of behavioral medicine

Published: November 14, 2022

The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.

The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.

Journal: Journal of diabetes science and technology

Published: September 29, 2022

Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.

Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.

Journal: The lancet. Diabetes & endocrinology

Published: September 28, 2022

Utility of Islet Cell Preparations From Donor Pancreases After Euthanasia.

Utility of Islet Cell Preparations From Donor Pancreases After Euthanasia.

Journal: Cell transplantation

Published: May 18, 2022

Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients.

Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: August 19, 2021

US food and drug administration (FDA) panel endorses islet cell treatment for type 1 diabetes: A pyrrhic victory?

US food and drug administration (FDA) panel endorses islet cell treatment for type 1 diabetes: A pyrrhic victory?

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Published: May 05, 2021

Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.

Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.

Journal: Lancet (London, England)

Published: February 19, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026